[Radiosensitization effects of nucleoside analogs].
D000212:Acyclovir / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000494:pharmacology; D003561:Cytarabine / Q000031:analogs & derivatives / Q000494:pharmacology; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000532:radiotherapy*; D051379:Mice; D008809:Mice, Inbred C3H; D009705:Nucleosides / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents; D014740:Vidarabine / Q000494:pharmacology; D014916:Whole-Body Irradiation
D000970:Antineoplastic Agents; D009705:Nucleosides; D011838:Radiation-Sensitizing Agents; D003561:Cytarabine; D001086:Arabinofuranosyluracil; C026023:fiacitabine; C043457:fialuridine; D014740:Vidarabine; C034935:clevudine; D000212:Acyclovir